# MTHFR C677T and A1298C: Enzyme Activity vs Clinical Meaning > Teaching residual-activity percentages, thermolabile biology, and why common SNPs are not rare disease. *Published 2026-07-10 · Updated 2026-07-10 · By Marcus Chen* In short **C677T** (thermolabile) and **A1298C** are common polymorphisms that lower residual MTHFR activity in a genotype-dependent way. Teaching values (CT ~65%, TT ~30%, 1298 CC ~60%) are not personal disease scores. **Severe MTHFR deficiency** is a different rare entity. Direct-to-consumer reports turned two SNPs into identity. Medical genetics treats them as frequent population variants whose biochemical effects are real, modest, and nutrient-modifiable—not automatic clotting disorders or proof you cannot use folic acid. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, prenatal vitamins, housing remediation plans, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What do C677T and A1298C change in the enzyme? MTHFR converts 5,10-methylene-THF to 5-MTHF. The C677T variant (c.665C>T, p.Ala222Val, rs1801133) produces a thermolabile enzyme with reduced activity and greater FAD instability. Classic teaching residual activities—about **65% for CT** and **30% for TT**—come from the Frosst-lineage literature and clinical summaries such as [Moll & Varga in Circulation](https://www.ahajournals.org/doi/10.1161/circulationaha.114.013311). A1298C (c.1286A>C, p.Glu429Ala) has a milder solo phenotype; homozygous CC is often described near **60%** residual activity. The two loci are in linkage disequilibrium. Combined findings usually mean compound heterozygosity in trans, historically around 50–60% of control activity, not a cis double-hit catastrophe. Triple-variant patterns are rare. The [ACMG 2013 guideline](https://www.nature.com/articles/gim2012165) remains the counseling backbone for what these genotypes do *not* justify clinically. GenotypeApprox residual activityPopulation / phenotype notes 677 CC~100%Wild-type reference 677 CT~65%Very common heterozygote 677 TT~30%~10–15% N. American Caucasians; >25% some Hispanic groups 1298 CC~60%Milder alone on folate/Hcy Compound 677/1298 hetero~50–60%Usually trans configuration Severe deficiency (rare)Often <<30% with clinical diseaseNot the DTC SNP kit ## How common are these variants, and what is the folate effect size? Because 677TT is frequent, any trait weakly associated with it will appear in huge absolute numbers of people without meaning the SNP is a monogenic disease. [CDC MTHFR facts](https://www.cdc.gov/folic-acid/data-research/mthfr/index.html) translate meta-analytic data that at equal folic acid intake, TT blood folate averages about **16% lower** than CC—modest and still responsive to standard supplementation. That is the opposite of cannot metabolize folic acid. Gene–nutrient interaction is the real story: genotype effects on total homocysteine and folate are largest when folate intake is low and shrink under fortification and supplementation. [Frosst et al. 1995](https://pubmed.ncbi.nlm.nih.gov/7647779/) launched the vascular-risk hypothesis era; later clinical guidelines pruned over-interpretation for thrombophilia panels. ## How should residual activity numbers be used in counseling? Quote them as approximate teaching values. Do not convert them into a personal methylation score, an anticoagulation trigger, or a reason to abandon folic acid for pregnancy-capable people. Separate 677TT (most studied, FAD-sensitive) from A1298C alone (weaker phenotype). Never equate consumer SNP panels with sequencing for severe deficiency. If genotype is already known, optional fasting homocysteine can add counseling granularity for TT, but phenotype and standard risk factors still drive care. Bottom line: enzyme kinetics explain why researchers study riboflavin and folate interactions; they do not license a wellness identity built on two SNPs. ## What should careful readers do with this evidence? Translate research into personal decisions carefully. Population averages, laboratory teaching values, and regulatory monitoring tables are not individualized prescriptions. Prefer primary sources—agency guidelines, peer-reviewed systematic reviews, and trial outcome papers—over social media summaries that collapse detection into danger or genotype into destiny. When a claim would change medications, pregnancy planning, major diet restriction, or expensive testing, demand an outcome study or a guideline that actually supports the action. When the claim is about shopping or home moisture control, weigh cost, feasibility, and whether the action also supports broader health goals such as eating more produce or fixing leaks. Keep differential diagnosis open. Fatigue, brain fog, subfertility, and nonspecific inflammation have many causes. Environmental and genetic axes can matter, but they compete with sleep, training load, iron status, thyroid disease, depression, infection, and medication effects. A rigorous approach sequences high-yield fundamentals first, then targeted evaluation, then optional optimization. That sequence is how you avoid both dismissiveness and cascade over-medicalization. Finally, re-check claims when new primary documents appear. Residue programs publish annual updates; prenatal guidance is reaffirmed on fixed cycles; building-science guidance evolves with moisture research. Update your mental model from the newest primary PDF, not from a screenshot of last decade's influencer slide. Editorial discipline means stating uncertainty out loud: residual enzyme activity percentages are teaching approximations; residue detection rates are not cancer probabilities; mycotoxin animal doses are not bedroom air doses. Readers deserve that precision even when it makes the story less dramatic. Health Canon grades actions by outcome evidence, not by how viral a pathway diagram becomes. If a protocol cannot name its effect size, population, and failure mode, it is not ready for first-line lifestyle theater. Editorial discipline means stating uncertainty out loud: residual enzyme activity percentages are teaching approximations; residue detection rates are not cancer probabilities; mycotoxin animal doses are not bedroom air doses. Readers deserve that precision even when it makes the story less dramatic. Health Canon grades actions by outcome evidence, not by how viral a pathway diagram becomes. If a protocol cannot name its effect size, population, and failure mode, it is not ready for first-line lifestyle theater. ## Sources 1. [ACMG MTHFR guideline](https://www.nature.com/articles/gim2012165) 2. [MTHFR patient guide](https://www.ahajournals.org/doi/10.1161/circulationaha.114.013311) 3. [MTHFR and folic acid facts](https://www.cdc.gov/folic-acid/data-research/mthfr/index.html) 4. [Frosst C677T identification](https://pubmed.ncbi.nlm.nih.gov/7647779/) --- Source: https://healthcanon.com/hormones-and-genes/mthfr-c677t-a1298c-enzyme-activity Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt